MOTS‐c promotes phosphorodiamidate morpholino oligomer uptake and efficacy in dystrophic mice
Abstract Antisense oligonucleotide (AO)‐mediated exon‐skipping therapies show promise in Duchenne muscular dystrophy (DMD), a devastating muscular disease caused by frame‐disrupting mutations in the DMD gene. However, insufficient systemic delivery remains a hurdle to clinical deployment. Here, we d...
Saved in:
| Main Authors: | Ning Ran, Caorui Lin, Ling Leng, Gang Han, Mengyuan Geng, Yingjie Wu, Scott Bittner, Hong M Moulton, HaiFang Yin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2020-12-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.202012993 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world phosphorodiamidate morpholino oligomer treatment patterns in Duchenne muscular dystrophy: a claims-based analysis
by: Shannon Grabich, et al.
Published: (2025-07-01) -
Using muscle homing peptide CyPep10 to deliver phosphorodiamidate morpholino oligomers in the mdx mouse
by: Anne-Fleur E. Schneider, et al.
Published: (2025-09-01) -
Efficacy and safety of Viltepso® in Duchenne muscular dystrophy: review of clinical studies
by: V. M. Suslov, et al.
Published: (2024-11-01) -
Modern methods of therapy of Duchenne muscular dystrophy: literature review with a clinical case
by: S. B. Artemyeva, et al.
Published: (2024-01-01) -
Possibility of exon skipping therapy for Duchenne muscular dystrophy in Russian patients: present and future
by: E. V. Zinina, et al.
Published: (2024-09-01)